DATA GRAPHICS | Data Byte
December highlights also include confirmation of non-renewal for Blenrep, plus recommendations for two therapies for neglected tropical diseases
By Gunjan Ohri, Data Content Analyst
December 16, 2023 12:06 AM UTC
At its December meeting, EMA’s CHMP recommended approval of three new medicines, Casgevy, Skyclarys and Velsipity, and label extensions for four. The agency also confirmed its non-renewal of Blenrep.
Just weeks after Casgevy exagamglogene autotemcel became the world’s first gene editing therapy via approval in the U.K., CHMP has recommended conditional approval of Casgevy for transfusion-dependent β-thalassemia and sickle cell disease. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650947/ema-s-chmp-green-lights-casgevy-skyclarys-and-velsipity